# Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam

> **NCT03353857** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 68 (actual)

## Conditions studied

- Biological Availability

## Interventions

- **DRUG:** levonorgestrel/ Microlut
- **DRUG:** Norethindrone/ Noriday
- **DRUG:** Desogestrel/ Cerazette
- **DRUG:** Dienogest/ Visanne
- **DRUG:** Drospirenone, Ethinylestradiol/ Yasmin
- **DRUG:** Midazolam/ Midazolam-ratiopharm
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT03353857
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2018-07-04
- **Final completion:** 2019-02-19
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03353857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03353857, "Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03353857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*